Archangels, a leading business angel syndicate investing in early stage Scottish life sciences and technology companies, is bolstering its funding fire power after securing a £12 million co-investment agreement with British Business Investments via its Regional Angels Programme.
The deal will provide the Edinburgh-based syndicate with additional capital to fuel the success of Scotland’s next-generation of entrepreneurs and innovators.
Archangels will deploy the capital from British Business Investments, a wholly owned commercial subsidiary of the British Business Bank, alongside syndicate funding across all of its investment activity.
Operating for over 30 years, Archangels is deeply committed to its long-term role in maximising investor returns, building and nurturing successful businesses and helping Scotland prosper. Archangels has invested over £160 million in the most innovative early stage companies, with disruptive technology, protectable IP and the potential to scale globally. In recent years, Archangels has enjoyed a number of significant exits, including the sale of medical AI business, Blackford Analysis, to Bayer Pharma.
